Intranasal ketamine versus intravenous morphine for older adults with musculoskeletal pain in the emergency department: a randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201229004

Enrollment

100

Registered

2020-12-29

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute musculoskeletal pain in elderly musculoskeletal muscle pain older elderly

Interventions

ketamine 0.3 mg per 1 kg of weight (calculated from the patient&#39

s actual weight in kg) packed in a Luer lock syringe&#44

added 0.1 ml after injection into both nasal passages. Store and dispose of used equipment in prepared containers according to hospital guidelines. And injected 5 ml of normal saline intravenously as

s actual weight in kg)&#44

placed in a syringe&#44

inserted into an infusion pump to administer the entire drug slowly within 10 minutes. Used equipment in a container prepared according to hospital guidelines. And sprayed saline solution (Normal sali

Active Comparator Drug,Active Comparator Drug

ketamine group,morphine group

Eligibility

Sex/Gender

All

Age

65 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Patient age more than 65 years presenting to the ED 2. Musculoskeletal pain within 7 days 3. Moderate to severe pain(Numeric rating scale 5-10)

Exclusion criteria

Exclusion criteria: 1. Lack of Informed consent 2. Hemodynamic instability ( SBP < 90 or > 180 mmHg, PR < 50 or > 150 bpms, RR < 10 or > 30 bpms) 3. History of acute head or eye injury 4. Seizure 5. Intracranial hypertension 6. Severe chronic obstructive pulmonary disease 7. Chronic pain 8. Psychological disorder 9. Immediate surgical intervention 10. Altered mental status 11. Alcohol and drug abuse 12. Nasopharyngeal deformity 13. Recent opioid use (4 hr before) 14. Ketamine and morphine allergy/addiction 15. Renal (CrCl <50) or hepatic insufficiency 16. Patients with a history of risk or exposure to COVID-19 disease according to the notification of the Department of Disease Control.

Design outcomes

Primary

Measure	Time frame
difference of numeric pain scale in patients who receive morphine and ketamine 0, 15, 30,45,60,75,90,105,120 min percentage	—

Secondary

Measure	Time frame
adverse event and rate of rescue therapy after medication 0, 15, 30,45,60,75,90,105,120 min percentage	—

Countries

Thailand

Contacts

Public ContactSuchada Tongbua

Navamindradhiraj University

Suchada.6784@gmail.com089-065-4841

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026